Genedrive PLC
D6M
Company Profile
Business description
Genedrive PLC is a holding company engaged in the molecular diagnostics business. It operates in one operating segment named Diagnostics which is engaged in the Genedrive Point of need molecular diagnostics platform for the diagnosis of infectious diseases and use in patient stratification (genotyping), pathogen detection, and other indications. Geographically the majority of the revenue is derived from the United Kingdom and also has its presence in Europe, United States of America and Rest of the World.
Contact
Grafton Street
The Incubator Building
ManchesterM13 9XX
GBRT: +44 1619890245
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
30 June 2026
Employees
43
Stocks News & Analysis
stocks
Lower production and higher prices for ASX hydrocarbon play
Improving pricing offsets severe weather impact on sales volumes.
stocks
Alphabet returns on AI investments accelerating
AI propels business across aegments, cloud is grightest; Increasing our fair value.
stocks
We lift our fair value estimate for this ASX energy play
Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,887.60 | 17.10 | 0.19% |
| CAC 40 | 7,980.81 | 91.32 | -1.13% |
| DAX 40 | 23,869.07 | 85.49 | -0.36% |
| Dow JONES (US) | 48,861.81 | 280.12 | -0.57% |
| FTSE 100 | 10,232.25 | 19.14 | 0.19% |
| HKSE | 25,770.67 | 341.17 | -1.31% |
| NASDAQ | 24,673.24 | 9.44 | 0.04% |
| Nikkei 225 | 59,284.92 | 632.54 | -1.06% |
| NZX 50 Index | 12,903.31 | 133.01 | 1.04% |
| S&P 500 | 7,135.95 | 2.85 | -0.04% |
| S&P/ASX 200 | 8,665.80 | 25.60 | 0.30% |
| SSE Composite Index | 4,112.16 | 4.65 | 0.11% |